- #357993
- 280
- Merck #00006489700
PedvaxHIB®Haemophilus Influenzae Type b Vaccine (Hib) Indicated for People 2 to 71 Months of Age 7.5 mcg / 0.5 mL Injection Single-Dose Vial 0.5 mL
PEDVAXHIB, VL 0.5ML (10/BX)
Features
- Each 0.5 mL dose of Liquid PedvaxHIB is a sterile product formulated to contain: 7.5 mcg of Haemophilus b PRP, 125 mcg of Neisseria meningitidis OMPC and 225 mcg of aluminum as amorphous aluminum hydroxyphosphate sulfate (previously referred to as aluminum hydroxide), in 0.9% sodium chloride, but does not contain lactose or thimerosal
- More …
Product Details Email
Product Specifications
McKesson # | 357993 |
Manufacturer # | 00006489700 |
Brand | PedvaxHIB® |
Manufacturer | Merck |
Country of Origin | United States |
Application | Haemophilus Influenzae Type b Vaccine (Hib) |
Container Type | Single-Dose Vial |
Dosage Form | Injection |
Generic Drug Code | 99344 |
Generic Drug Name | Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) |
NDC Number | 00006489700 |
Product Dating | McKesson Acceptable Dating: we will ship >= 180 days |
Storage Requirements | Requires Refrigeration |
Strength | 7.5 mcg / 0.5 mL |
Type | Intramuscular |
UNSPSC Code | 51201627 |
User | Indicated for People 2 to 71 Months of Age |
Volume | 0.5 mL |
Features
- Each 0.5 mL dose of Liquid PedvaxHIB is a sterile product formulated to contain: 7.5 mcg of Haemophilus b PRP, 125 mcg of Neisseria meningitidis OMPC and 225 mcg of aluminum as amorphous aluminum hydroxyphosphate sulfate (previously referred to as aluminum hydroxide), in 0.9% sodium chloride, but does not contain lactose or thimerosal
More Information
Professionals Also Viewed
- #1028203
- 144
- Glaxo Smith Kline #58160081811
- HIBERIX is a vaccine indicated for active immunization for the prevent …
- HIBERIX is approved for use in children 6 weeks through 4 years of age …
- 10 single dose vials of lyophilized vaccine
- #1026991
- 415
- Sanofi Pasteur #545-03
- ActHIB is a vaccine indicated for the prevention of invasive disease c …
- ActHIB vaccine is approved for use as a four dose series in infants an …